692 related articles for article (PubMed ID: 14651017)
1. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
Alván G
Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
[No Abstract] [Full Text] [Related]
2. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
3. Data protection: an anti-generic weapon.
Prescrire Int; 2003 Dec; 12(68):235. PubMed ID: 14986701
[No Abstract] [Full Text] [Related]
4. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
5. America's other drug problem: how the drug industry distorts medicine and politics.
Relman AS; Angell M
New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
[No Abstract] [Full Text] [Related]
6. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
Kraushaar KJ
Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
[No Abstract] [Full Text] [Related]
7. Prescription drugs and health care reform.
Gibaldi M
Pharmacotherapy; 1993; 13(6):583-9. PubMed ID: 8302681
[No Abstract] [Full Text] [Related]
8. [Marketing of pediatric drugs].
Pabst JY
Soins Pediatr Pueric; 2003; (210):18-9. PubMed ID: 12683130
[No Abstract] [Full Text] [Related]
9. Correcting Hatch-Waxman.
Fernandes M
Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
[No Abstract] [Full Text] [Related]
10. The response to health care reform by the pharmaceutical industry.
Krulwich AS
Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
[No Abstract] [Full Text] [Related]
11. Pharmaceutical policy in Italy: towards a structural change?
Ghislandi S; Krulichova I; Garattini L
Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
[TBL] [Abstract][Full Text] [Related]
12. Congress works to permit 'biosimilar' drugs very soon.
Carroll J
Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
[No Abstract] [Full Text] [Related]
13. Path to approval proves rocky for copycat biodrugs.
Wadman M
Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
[No Abstract] [Full Text] [Related]
14. Lessons from Eprex for biogeneric firms.
Louët S
Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
[No Abstract] [Full Text] [Related]
15. Patent nonsense: evidence tells of an industry out of social control.
Mintzberg H
CMAJ; 2006 Aug; 175(4):374. PubMed ID: 16908900
[No Abstract] [Full Text] [Related]
16. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
Adamini S; Maarse H; Versluis E; Light DW
J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic-class wars--drug promotion in a competitive marketplace.
Kessler DA; Rose JL; Temple RJ; Schapiro R; Griffin JP
N Engl J Med; 1994 Nov; 331(20):1350-3. PubMed ID: 7935706
[No Abstract] [Full Text] [Related]
18. Improving the PPI sample for prescription pharmaceuticals.
Kelly GG
Mon Labor Rev; 1997 Oct; 120(10):10-7. PubMed ID: 10176326
[No Abstract] [Full Text] [Related]
19. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
20. EU directive on clinical trials penalizes small sponsors.
Meldolesi A
Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
